Highly efficient antigen targeting to M-DC8+ dendritic cells via FcγRIII/CD16-specific antibody conjugates

International Immunology

Volumn 17, Issue 5, 2005, Pages 539-547

  Mende, Ines ^a   Hoffmann, Patrick ^a   Wolf, Andreas ^a   Lutterbüse, Ralf ^a   Kopp, Eugen ^b   Baeuerle, Patrick A ^a   de Baey, Annegret ^c   Kufer, Peter ^a,b  

^a MICROMET AG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Techno Venture Management   (Germany)

Author keywords

Antibodies; Antigen presentation; Dendritic cells; Fc receptors; Vaccination

Indexed keywords

ANTIBODY CONJUGATE; CD16 ANTIGEN; CD4 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; HEPATITIS C VIRUS NONSTRUCTURAL PROTEIN 3; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE; VIRUS PROTEIN;

ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ARTICLE; CELL SUBPOPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS LINKING; CROSS PRESENTATION; DENDRITIC CELL; DRUG POTENCY; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR RECOGNITION; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; VACCINATION;

ANTIBODIES; ANTIGEN PRESENTATION; ANTIGENS; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; DENDRITIC CELLS; HUMANS; IMMUNOCONJUGATES; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; RECEPTORS, IGG; TETANUS TOXIN; VACCINES;

EID: 21244473186     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxh232     Document Type: Article

References (41)

1. Banchereau, J. and Steinman, R. M. 1998. Dendritic cells and the control of immunity. Nature 392:245.
2. Heath, W. R. and Carbone, F. R. 2001. Cross-presentation in viral immunity and self-tolerance. Nat. Rev Immunol. 1:126.
3. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C. and Amigorena, S. 2002. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20:621.
4. Meidenbauer, N., Andreesen, R. and Mackensen, A. 2001. Dendritic cells for specific cancer immunotherapy. Biol. Chem. 382:507.
5. Zhou, Y., Bosch, M. L. and Salgaller, M. L. 2002. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J. Immunother. 25:289.
6. Nestle, F. O., Banchereau, J. and Hart, D. 2001. Dendritic cells: On the move from bench to bedside. Nat. Med. 7:761.
7. Wang, H., Griffiths, M. N., Burton, D. R. and Ghazal, P. 2000. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc. Natl Acad. Sci. USA 97:847.
8. Rodriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P. and Amigorena, S. 1999. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell. Biol. 1:362.
9. Regnault, A., Lankar, D., Lacabanne, V. et al. 1999. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:371.
10. Kita, H., Lian, Z. X., Van de Water, J. et al. 2002. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J. Exp. Med. 195:113.
11. Dhodapkar, K. M., Krasovsky, J., Williamson, B. and Dhodapkar, M. V. 2002. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195:125.
12. Schakel, K., Mayer, E., Federle, C., Schmitz, M., Riethmuller, G. and Rieber, E. P. 1998. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur. J. Immunol. 28:4084.
13. de Baey, A., Mende, I., Riethmueller, G. and Baeuerle, P. A. 2001. Phenotype and function of human dendritic cells derived from M-DC8(+) monocytes. Eur. J. Immunol. 31:1646.
14. Traunecker, A., Oliveri, F. and Karjalainen, K. 1991. Myeloma based expression system for production of large mammalian proteins. Trends Biotechnol. 9:109.
15. Diepolder, H. M., Gruener, N. H., Gerlach, J. T., Jung, M. C., Wierenga, E. A. and Pape, G. R. 2001. Different levels of T-cell receptor triggering induce distinct functions in hepatitis B and hepatitis C virus-specific human CD4(+) T-cell clones. J. Virol. 75:7803.
16. zum Buschenfelde, C. M., Metzger, J., Hermann, C., Nicklisch, N., Peschel, C. and Bernhard, H. 2001. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J. Immunol. 167:1712.
17. Oi, V. T., Glazer, A. N. and Stryer, L. 1982. Fluorescent phycobili-protein conjugates for analyses of cells and molecules. J. Cell Biol. 93:981.
18. Bochner, B. S., McKelvey, A. A., Schleimer, R. P., Hildreth, J. E. and MacGlashan, D. W., Jr. 1989. Flow cytometric methods for the analysis of human basophil surface antigens and viability. J. Immunol. Methods 125:265.
19. Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G. and Lanzavecchia, A. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237.
20. Tamm, A. and Schmidt, R. E. 1996. The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding. J. Immunol. 157:1576.
21. Edberg, J. C. and Kimberly, R. P. 1997. Cell type-specific glycoforms of Fc gamma RIIIa (CD16): Differential ligand binding. J. Immunol. 159:3849.
22. Klein, J. and Sato, A. 2000. The HLA system. First of two parts. N. Engl. J. Med. 343:702.
23. Steinbrink, K., Jonuleit, H., Muller, G., Schuler, G., Knop, J. and Enk, A. H. 1999. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 93:1634.
24. Jonuleit, H., Schmitt, E., Schuler, G., Knop, J. and Enk, A. H. 2000. Induction of interleukin 10-producing, non proliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192:1213.
25. Bonifaz, L. C., Bonnyay, D. P., Charalambous, A. et al. 2004. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199:815.
26. Sallusto, F., Cella, M., Danieli, C. and Lanzavecchia, A. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products. J. Exp. Med. 182:389.
27. Schakel, K., Kannagi, R., Kniep, B. et al. 2002. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 17:289.
28. Steinbrink, K., Wolfl, M., Jonuleit, H., Knop, J. and Enk, A. H. 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159:4772.
29. de Baey, A., Mende, I., Baretton, G. et al. 2003. A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J. Immunol. 170:5089.
30. Engering, A., Geijtenbeek, T. B., van Vliet, S. J. et al. 2002. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J. Immunol. 168:2118.
31. Schjetne, K. W., Thompson, K. M., Aarvak, T., Fleckenstein, B., Sollid, L. M. and Bogen, B. 2002. A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Int. Immunol. 14:1423.
32. Hart, J. P., Gunn, M. D. and Pizzo, S. V. 2004. A CD91-positive subset of CD11c+ blood dendritic cells: Characterization of the APC that functions to enhance adaptive immune responses against CD91-targeted antigens. J. Immunol. 172:70.
33. Machy, P., Serre, K. and Leserman, L. 2000. Class I-restricted presentation of exogenous antigen acquired by Fcgamma receptor-mediated endocytosis is regulated in dendritic cells. Eur. J. Immunol. 30:848.
34. Toes, R. E., Nussbaum, A. K., Degermann, S. et al. 2001. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. 194:1.
35. Azuma, M., Phillips, J. H. and Lanier, L. L. 1993. CD28-T lymphocytes. Antigenic and functional properties. J. Immunol. 150:1147.
36. Groh, V, Rhinehart, R., Randolph-Habecker, J., Topp, M. S., Riddell, S. R. and Spies, T. 2001. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2:255.
37. Roberts, A. I., Lee, L., Schwarz, E. et al. 2001 NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J. Immunol. 167:5527.
38. Guyre, C. A., Barreda, M. E., Swink, S. L. and Fanger, M. W. 2001. Colocalization of Fc gamma RI-targeted antigen with class I MHC: implications for antigen processing. J. Immunol. 166:2469.
39. Wallace, P. K., Tsang, K. Y., Goldstein, J. et al. 2001. Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. J. Immunol. Methods 248:183.
40. Thurner, B., Haendle, I., Roder, C. et al. 1999. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669.
41. Tjoa, B. A., Simmons, S. J., Bowes, V. A. et al. 1998. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36:39.